Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease
Brian G. Feagan(Western University), David J. Chang(Yale University), A. C. Maroney(GlaxoSmithKline (United States)), Séverine Vermeire(KU Leuven), Richard N. Fedorak(University of Alberta), Ian C. Lawrance(The University of Western Australia), Ursula Seidler(Medizinische Hochschule Hannover), William J. Sandborn(University of San Diego), Matthieu Allez(Inserm), Geert D’Haens(Amsterdam University Medical Centers), A. Heath(GlaxoSmithKline (United States)), C H Jurgensen(GlaxoSmithKline (United States)), S D Lee(University of Washington)
Cited by 110
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k